Feedback
HLA-B*15:02 Genotyping, Carbamazepine Hypersensitivity
2012049
Ordering Recommendation

Identify patients prior to treatment with carbamazepine (CBZ) who may be at risk for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Recommended for patients not currently taking carbamazepine.

Mnemonic
HLA B1502
Methodology
Polymerase Chain Reaction/Sequence Specific Oligonucleotide Probe Hybridization
Performed
Mon-Fri
Reported
3-7 days
N/A
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 5 mL whole blood. (Min: 3 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Specimens collected in green (sodium or lithium heparin). 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Background Information for HLA-B*1502 Genotype, Carbamazepine Hypersensitivity:
Characteristics:
Carbamazepine (CBZ) is an aromatic antiepileptic drug, approved for the treatment of epilepsy and trigeminal neuralgia. Rarely, CBZ can induce severe life threatening reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Symptoms usually appear within the first months of treatment, and include skin rash, hives, sores in the mouth, blistering or peeling of the skin, and erosion of the mucous membranes in the respiratory and gastrointestinal tract. The presence of HLA-B*15:02 increases risk for CBZ-induced SJS/TEN in individuals of Asian ancestry. The incidence of CBZ-induced life-threatening reactions such SJS, TEN, or hypersensitivity syndrome (HSS) is 1-10 per 10,000, which can be higher in some Asian countries.
Incidence: HLA-B*15:02 allele frequency varies by ethnicity, with highest incidence in Asians: 10.2 percent in Han Chinese, 10 percent in Taiwanese (18 percent in indigenous Puyuma), greater than 5 percent in the populations of Hong Kong, Thailand, Malaysia, Vietnam, Philippines, India (Khandesh and West Bhil) and Indonesia. Frequency is low in African Americans (0.1-1 percent) and less than 0.1 percent in Caucasians.
Cause: In patient of Asian descent, CBZ-induced SJS/TEN is strongly associated with the presence of HLA-B*15:02 allele. The mechanism is immune mediated and involves drug-induced changes in peptide presentation by HLA-B*15:02, which allows for the activation of self-reactive T lymphocytes. Activated immune cells contribute to the cellular death of keratinocytes in the skin, which causes the epidermal destruction and detachment of the skin seen in SJS/TEN.
Alleles tested: HLA-B*15:02 allele.
Clinical Sensitivity and Specificity: 80-97 percent and 99 percent, respectively in populations where the HLA-B*15:02 allele is common.
Methodology: PCR followed by Sequence Specific Oligonucleotide Probe Hybridization of HLA-B locus.
Analytical Sensitivity & Specificity: Greater than99 percent.
Limitations:
Copy number of HLA-B*15:02 allele will not be reported. Other genetic and non-genetic factors that influence carbamazepine hypersensitivity are not evaluated. Other rare, undocumented alleles may occur which may or may not give false positive results.

Components
Component Test Code*Component Chart NameLOINC
2012050HLA-B*15:02
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • HLA B*1502, Carbamazepine Sensitivity
  • HLA-B 1502 Genotype, Carbamazepine Hypersensitivity
  • HLA-B*1502 Typing

Performed at UUHC - H&I Lab